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Abstract
Background: Optimal management for adhesive shoulder capsulitis (frozen shoulder) is currently unclear. We intended
to explore whether treatment by intra-articular injections with corticosteroid and distension is more effective than
treating with corticosteroids alone or treatment-as-usual in a primary care setting in Norway.
Methods: In this prospective randomised intention to treat parallel study, 106 patients were block randomised to three
groups; 36 (analysed 35) receiving steroid injection and Lidocaine (IS), 34 receiving steroid and additional saline
as distension (ISD) and 36 had treatment-as-usual (TAU). Intervention groups received four injections within 8 weeks,
assessed on 1st visit, at the 4th and 8th week. Outcomes were Shoulder Pain and Disability Index (SPADI), Numerical
pain rating scale (NPRS) and passive range of motion (PROM). Postal assessment was repeated after 1 year for SPADI.
Patients in the IS and ISD groups were “blinded” for intervention received and the assessor was “blinded” to group
allocation.
Results: At baseline there were no differences between groups in outcome measures. There were no statistical
significant differences between the intervention groups in SPADI, NPRS and PROM at baseline, at short-term
(4-and 8 weeks) or long-term (12 months). There were statistically significant differences (p < 0.01) in change
scores at short-term for SPADI when comparing the IS and TAU groups (-20.8; CI-28.9 to -12.7), and the ISD and
TAU groups (-21.7; CI-29.4 to -14.0), respectively for NPRS (-2.0; CI-2.8 to -1.1 and -2.2; CI-3.0 to -1.4), and for PROM,
but not at long-term for SPADI (p > 0.05).
Effect size (ES) at 8 weeks was large between both injection groups and TAU (ES 1.2). At 12 months ES was
reduced to 0.3 and 0.4 respectively. Transitory side effects as flushing and after-pain were reported by 14 % in
intervention groups.
Conclusion: This intention to treat RCT in primary care indicates that four injections with corticosteroid with or
without distension, given with increasing intervals during 8 weeks, were better than treatment-as-usual in treatment of
adhesive shoulder capsulitis. However, in the long run no difference was found between any of the groups, indicating
that natural healing takes place independent of treatment or not.
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Background
Adhesive capsulitis of the shoulder, also called frozen shoul-
der, has a prevalence of 2 to 5 % of the general population,
but among diabetic patients the prevalence ranged from 11
to 30 % [1, 2]. There is a strong correlation between adhe-
sive capsulitis and other medical conditions such as dia-
betes, rheumatic disease, heart disease, hyperthyreosis [3].
Adhesive capsulitis occurs mostly in middle age [4–6] and
women between 50 and 60 years are most commonly
affected [7]. Both shoulders can be affected simultan-
eously and/or the other side can be affected a few years
later [7, 8]. Shoulder stiffness and pain interferes con-
siderably with activities of daily living, and may be asso-
ciated with increased sick leave in people of working
age and incapacity in the elderly.
Adhesive capsulitis is a long-lasting disorder with spon-
taneous onset of pain and progressive stiffness [9]. It gener-
ally involves reduced movement of the gleno-humeral joint
in several planes, with most restriction of external rotation,
some restriction of abduction and least affection of internal
rotation carried out passively, also called the capsular
pattern [5, 6]. Adhesive capsulitis is primarily a clinical
diagnosis and radiography can be complementary in the
diagnosis [10, 11]. Pathophysiologically, thickening and
contracture of the inferior capsule [12], contracture of the
rotator interval, coraco-humeral ligament and anterior cap-
sule with a combination of synovial inflammation and cap-
sular fibrosis, has been described [10]. Bunker et al. found
the histo-pathological picture comparable to Dupuytren’s
disease of the hand with no inflammation and no synovial
involvement [13]. The natural history remains contro-
versial. Earlier studies considered the condition as self-
limiting, lasting for 2 to 3 years, reporting that the
majority of patients would get almost complete recov-
ery or full recovery [14, 15]. Other authors report long-
term pain and stiffness for several years [16–18]. For
convenience, the condition is divided into three phases;
the painful phase lasting from 3 to 9 months, followed
by a freezing phase with progressive stiffness lasting
from 4 to 12 months and finally, the recovery phase
with gradual return of movement, lasting 5–26 months
[19, 20]. Some have divided the condition into four
stages, based on the correlation of findings on physical
examination and arthroscopic examination [21].
Commonly used conservative therapies for adhesive
capsulitis include non-steroidal anti-inflammatory drugs,
intra-articular glucocorticosteroid injections, oral gluco-
corticosteroid medication, physical therapy, manipulation
under anaesthesia and hydrodilatation [22]. However, des-
pite the amount of research in the topic, results still ap-
pear to be inconclusive regarding effectiveness of the
different treatment modalities [23, 24]. In hydrodilatation
or arthrographic distension procedures, an intra-articular
injection is performed under fluoroscopy with local
anaesthetics, normal saline and often with contrast
medium. Most of the interventional studies with cortico-
steroid injections, with or without hydrodilatation (disten-
sion), have been done with single corticosteroid injection
under fluoroscopy or ultrasound guided, either sub-
acromial or intra-articular or both. Van der Windt et al.
[25] used up to a maximum of three intra-articular injec-
tions over 6 weeks. According to Cyriax’s treatment
method [1], adhesive capsulitis is often treated with be-
tween three to six corticosteroid intra-articular injections
with increasing interval between injections, which is also
supported by others [4–6, 26]. A short term efficacy of
arthrographic distension with normal saline and cor-
ticosteroid versus placebo was demonstrated in a ran-
domised controlled trial (RCT) in patients with painful
stiff shoulder [27]. A systematic Cochrane review regarding
efficacy of hydrodilatation concludes: “there is “silver” level
evidence that arthrographic distension with saline and ster-
oid provides short-term benefits in pain, range of move-
ment and function in adhesive capsulitis. It is uncertain
whether this is better than alternative interventions” [28].
Hydrodilatation studies [29–31] did not demonstrate any
statistically significant differences in functional outcome
compared to steroid injection [32].
The present study has followed the existing practice of
treating patients with adhesive capsulitis in primary care
in Norway. In a pilot trial, there was no clinically signifi-
cant difference in overall results between corticosteroid
alone and corticosteroid with distension [33]. The aim of
this study was to elucidate the effect, if any, of multiple
corticosteroid injections with distension as compared to
multiple corticosteroid injections alone, to treatment-as-
usual.
Methods
This RCT comprises two parallel intervention groups
and a control group allocating equal number of patients.
The intervention period lasted 8 weeks, with a postal
follow-up after 1 year. The patients were recruited from
the city of Bergen and neighboring municipalities by re-
ferral from primary care (PC) practitioners from January
2010 to October 2013.
Included patients had to be above 18 years of age, should
be able to understand and speak Norwegian, and have no
contraindication for use of corticosteroids. Patients should
have reduced passive range of motion (PROM) with a
reduction of more than 30 % of two of three shoulder
movements and none of the three movements (Abduction
=ABD, External rotation = ER and Internal rotation = IR)
should be normal. Patients with diabetes, asthma, preg-
nant women and breast feeding mothers were excluded
from the study. Female patients in fertile age were asked
about prevention.
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Eligible patients were invited to participate in the
study were randomly assigned to one of three groups ac-
cording to serial no. on the closed envelope by one of
authors (SPS). The block randomisation, using a block
size of three, was carried out by one of the supervisors
(AB). Possible permutations were strung together using
a random cipher table. The resulting information on
treatment was printed out and put in a closed envelope
with the patient serial number outside. The envelope
was to be opened after the inclusion of the patient.
Treatment allocation was thereby “blinded” for both re-
searcher and patient at the point of inclusion. The pa-
tients in the active intervention groups were not
informed which treatment option (with or without dis-
tension) was carried out.
Intervention
Intra-articular injections were administered by land-
marks using posterior approach thus preventing the pa-
tients from seeing the size of syringe used. This was to
avoid possible bias as the patients might consider treat-
ment with distension and corticosteroid to be superior
to corticosteroid alone. The injections were administered
by one of the authors (SPS) who is both a general practi-
tioner and a physiotherapist at a primary care center in
municipality of Bergen and has several years of experi-
ence in treating adhesive capsulitis by intra-articular in-
jections both by landmarks and ultrasound guided.
Patients in the steroid alone group (IS) received Tri-
amcinolone 20 mg injection, with Lidocaine 10 mg/ml
3 ml and a total of 4 ml solution. Those in the distension
group (ISD) also received steroid and Lidocaine (Triam-
cinolone 20 mg, 3 ml Lidocaine), but with additional
physiological Sodium chloride 9 mg/ml, comprising a
total volume from 8 ml and upwards to 20 ml. Limiting
factors for injected volume were difficulty in further in-
jection and/or increasing pain during injection. Injection
to IS and ISD groups were given after inclusion on day
1, after 7, 17, and 31 days from the start. Adherence to
planned intervention was assessed continuously by one
of the authors (SPS). Patients receiving treatment-as-
usual (TAU) were informed about the possibilities of
optional conservative treatment, such as physiotherapy
or pain medication other than corticosteroid injections
or per oral corticosteroid medication until 61 days after
inclusion.
Outcome measures
The primary outcome was the Shoulder pain and disabil-
ity index (SPADI), which measures a combination of
pain and functional disability on a score from 0 to 100, a
high score indicating more pain and disability [34]. The
second outcome measure was pain intensity on average
for the previous 7 days, measured on a 10-point
Numerical pain rating scale (NPRS), where 0 meant no
pain and 10 meant unbearable pain. PROM was mea-
sured in sideways elevation (abduction), internal rotation
(by “Hand behind back” method) and external rotation. A
plurimeter, found to be a reliable gravity inclinometer, was
used as the measuring instrument for PROM [35–37].
PROM was measured, also on the normal side, on all
visits. PROM was measured in supine lying position for
external and internal rotation, and for abduction in stand-
ing. The endpoint was when the arm could not be moved
more or the pain became unbearable. To avoid discrepan-
cies in measurements due to affection of movements of
thumb joints, the distance in Hand-behind-back was mea-
sured in centimeters between the styloid process of the ra-
dius to the posterior inferior iliac spine. PROM was
measured by a research collaborator (a GP) being unaware
which group the patients were randomised to. The asses-
sor who took PROM had experience in use of the pluri-
meter, and had shown acceptable inter-tester reliability
[37]. The assessor made entries of the PROM on a separ-
ate paper so that confidentiality was maintained from the
treating doctor throughout the study.
The time intervals between the consecutive treatments
were 1, 1½ and 2 weeks. The control group remained
without treatment with corticosteroids in injection or tab-
let form until 61 days, but could use NSAIDs, Paracetamol
or Codeine as needed. SPADI and NPRS were registered
on the first visit, after 4 and 8 weeks. The 1 year follow-up
for SPADI was only by postal communication.
Sample size
For SPADI, being the primary outcome measure, we con-
sidered an outcome of 20 % better or worse to be clinically
significant. This represents a difference in score of 14 at
the level of SPADI = 70. Others have considered a differ-
ence in score of ≥10 to represent clinically important
change [34, 38]. In a previous study where SPADI was a
primary outcome measure, the variance in SPADI was
19.8 [27]. Given α = 0.05, we calculated the sample size to
be 31 in each group to have an 80 % power to detect a dif-
ference in mean SPADI score of ≥14. With a 10 % drop
out the number of patients required for the study to have
the above mentioned power were calculated to be 34 in
each group.
Statistical analysis
Differences in outcome between the groups were analyzed
using repeated measure ANCOVA and regression based
ANCOVA. In our analysis we have distinguished between
short-term follow-up (4 and 8 weeks) and long-term
follow-up (12 months). Since the 4 and 8 weeks data were
not independent, we chose to analyze these data as mul-
tiple follow-up observations. This was done in a repeated
measures ANCOVA model with 4 and 8 weeks
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observations as repeated measures to capture the main ef-
fect of treatment between groups [39] (p.197), and with
pretest as a covariate to adjust for baseline differences be-
tween subjects. Similarly, we analyzed the long-term
follow-up data in another ANCOVA model using a regres-
sion procedure with the 12 months observations as
dependent variable, group as a categorical independent
variable and pretest as a covariate. In an additional/sec-
ondary analysis we added other independent variables
(specified) to both ANCOVA models to control for pos-
sible confounding.
Effect size (ES) for mean change in SPADI was also
calculated by subtracting post-test score (8 weeks and
12 months) from baseline in two groups, dividing it by
the standard deviation (SD) of the change score:
Effect size ¼ Mean of intervention group½ − Mean of treatment−as−usual group½ 
Standard Deviation
An ES of 0.8 is considered large and of crucial prac-
tical or clinical importance, while an ES of 0.2 is consid-
ered to be small and without any practical or clinical
importance [39].
We performed intention to treat (ITT) analysis [40],
keeping patients in their original allocations on random-
isation in accordance with ITT principles [41]. We had
intervention data for all patients until 8 weeks except for
missing data for two patients for 4 weeks and one pa-
tient for 8 weeks. One year follow-up data was lacking
for six patients. Missing data were imputed following
ITT principles.
Software package IBM SPSS Statistics 22 for Windows,
was used for all statistical analyses.
We have followed the CONSORT (Consolidated Stan-
dards of Reporting Trials) 2010 guidelines for reporting of
parallel group randomised trials. Figure 1 included in the
manuscript has followed 2010 CONSORT Flow Diagram
template. CONSORT 2010 Checklists for Randomised
Trials, CONSORT extension for Abstracts Checklist and
TIDieR (Template for Intervention Description and Repli-
cation) checklist files.
Results
Of the 216 patients referred for the study, 146 met the
inclusion criteria, whereof 40 patients declined to par-
ticipate for fear of coming in the TAU group and not re-
ceiving treatment immediately. Seventy patients were
excluded as they were less affected than the specified
criteria for reduced ROM or had diabetes. One hundred
and six patients were randomised for participation.
Thirty-six patients were allocated to the IS group, 34 pa-
tients to the ISD group, and 36 patients to TAU (Fig. 1).
All completed the specified intervention until 8 weeks,
and there were no dropouts, except for one in the IS
group. After 1 year 100 patients (95 %) answered the
postal questionnaire. One year follow up ended in
December 2014. No interim analysis was carried out
during the trial.
Patient characteristics
Baseline characteristics of all the included patients are
displayed in Table 1. The three groups were comparable
in their baseline regarding age, gender, mean duration of
shoulder pain, concurrent neck pain, previously frozen
shoulder, number of affected right side and dominant
side and sick leaves. There were no statistically signifi-
cant differences between the three groups regarding side
affected, operated shoulder prior to adhesive capsulitis,
trauma to shoulder (traumatic adhesive capsulitis), pre-
vious shoulder treatment, and smoking. There was a sta-
tistically significant difference in use of analgesics at
baseline between the two intervention groups (p < 0.05),
but not between the injection groups and TAU. Further-
more, 11 patients in the distension group had “trauma
to shoulder” whereas the IS group had two and the TAU
had three patients with previous trauma.
Intervention
Thirty-five patients in the IS group and 34 patients in
the ISD group received four injections each within the
time frame of 8 weeks. After the intervention period of
8 weeks, 12 patients (33 %) in the TAU group received
additional treatment with intra-articular injections with
corticosteroid and Lidocaine, same as in the IS group,
for pain relief, and three were operated. During the
8 weeks after recruitment, 11 patients in the TAU group
had received NSAIDs and/or pain killers as needed, and
three patients had received acupuncture for pain relief.
All three groups showed clinically significant change in
SPADI from baseline to 8 weeks (>14 points improve-
ment), although both intervention groups had improved
significantly more as compared to the TAU group at
8 weeks. Similarly, there was a significant improvement in
NPRS at 8 weeks for both intervention groups, but less in
the TAU group. Change in PROM for abduction was
slightly better between the distension group (54° increased
to 69°; i.e. 15° increase) and the TAU group (51° increased
to 57°; i.e. 6° increase) at 8 weeks (Table 2).
Both intervention groups had equivalent ES concern-
ing SPADI at 8 weeks (ES 1.2) and 12 months (ES 0.3
and 0.4) (Table 3). At 12 months, however, the change in
the TAU group was as large as the change in the two
intervention groups and no statistical significant differ-
ence was found in SPADI between the three groups,
illustrated in Fig. 2.
Repeated measure ANCOVA for short-term and re-
gression based ANCOVA for long-term revealed no
statistically significant difference between the two inter-
vention groups in SPADI, NPRS and PROM, neither at
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baseline, nor at short-term, or in SPADI at long-term. A
statistically significant change (p <0.001) was found for
both intervention groups when compared to the TAU
group at short-term for SPADI and NPRS. There was a
statistically significant difference (p < 0.01) at short-term
for all PROMs between the two injection groups and TAU
(Table 4).
In the TAU group, three patients were operated after
8 weeks, and 12 patients chose to receive intra-articular
corticosteroid injections without distension. In the
intention-to-treat analysis at 12 months, including all
patients in the groups to which they were allocated,
there were no significant differences between any of the
groups regarding change in SPADI (Table 4).
In our study there was only one drop out up to 8 weeks
and we did not expect this to affect the results substantially.
A secondary per-protocol analysis was performed excluding
the 15 patients that did not follow the initial TAU protocol
after the 8 week period. This did not affect the results.
However, we do acknowledge the fact that exclusion of
these patients lowers the sample power for the TAU group.
Five patients (14 %) in the IS group, eight patients
(24 %) in ISD group and six patients (14 %) in the TAU
group were still on sick leave after 1 year. Eight patients
Fig. 1 Flow diagram for randomisation and follow-up
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(22 %) in the IS group, nine patients (26 %) in the ISD
group and three patients (8 %) in the TAU group were
still on medication for shoulder pain at 12 months
follow-up.
Six patients (17 %) in the IS group and four (12 %) pa-
tients in the ISD group experienced minor transitory side-
effects such as flushing and after-pain. No incidences of
other side effects were reported. Patients in the two injec-
tion groups were asked to guess to which group they
belonged to after the last injection. Twenty-six patients
(38 %) guessed the wrong group.
Discussion
Repeated intra-articular steroid injections given with in-
creasing intervals in the gleno-humeral joint gives short-
term (8 weeks) benefit. Added capsular distension did
not significantly affect the outcome measures for SPADI,
NPRS and PROM. However, at long-term follow-up,
those who had received no intervention did equally well.
Earlier studies combining distension (10 ml) and cortico-
steroid versus distension alone and corticosteroid alone,
have reported better results for distension [42]. While in
studies by Corbeil et al. & Tveitå et al. [30, 31] no signifi-
cant differences between distension and non–distension
arthrography with corticosteroids were found, the main ef-
fect might therefore be attributed to corticosteroid alone.
Comparing our results between ISD group and TAU group
with Tveitå et al. [31], our study has demonstrated larger
improvement; for SPADI 24 versus 6, for ABD 15.4 versus
2, for ER 18.7 versus 2 and for IR 12.3 versus 3 respect-
ively. A systematic review concluded with “silver level”
evidence for short–term efficacy in pain, ROM, and
function of shoulder by arthrographic saline distension
and corticosteroid in patients with adhesive capsulitis
[28]. Studies with distension and corticosteroid causing
capsular rupture performed in hospital settings have also
shown significant results [27, 29, 42]. These and other case
series studies in primary care with distension and capsular
rupture [43, 44] are, however, not comparable to the
present study, as capsular rupture was not the intended
intervention. We cannot however rule out that capsular
rupture might have occurred in some patients. Tveitå et
al. [31] have observed capsular rupture at a volume as low
as 10 ml.
A dose of 20 mg Triamcinolone was a tradeoff dose be-
tween effect and side effects in both intervention groups
and is the generally accepted and practiced treatment dose
for adhesive capsulitis in primary care. A study by de Jong
[45] has shown better effect with a dose of 40 mg Triam-
cinolone than with 10 mg, whereas another study by Yoon
et al. [46] found no significant difference in outcome be-
tween a dose of 20 and 40 mg Triamcinolone. In this
study we used a series of injections, a total of four over a
period of 8 weeks. Many studies with distension have only
used a single corticosteroid injection, which makes com-
parison difficult. Only a few studies have used multiple in-
jections and even fewer have used multiple injections with
dilatation [25, 29, 31, 42, 47]. A review has concluded that
multiple injections improve pain and ROM in short term
from 6 to 16 weeks from the first injection. There is evi-
dence that up to three injections can be beneficial and
limited evidence that up to six injections is beneficial [4].
This study has followed the actual practice of treating
these patients in primary care with intra-articular injec-
tions by landmarks, without fluoroscopic guidance. Some
studies with ultrasound guided intra-articular steroid
Table 1 Baseline characteristics of patients
Characteristics Injection group Steroid alone (IS) Injection group Steroid and saline (ISD) Treatment-as-usual (TAU) group
Number and % within group
n = 36
Number and % within group
n = 34
Number and % within group
n = 36
Mean age (years) 52 (8.3) 53 (9.2) 54 (6.9)
Female 21 (58 %) 21 (62 %) 19 (53 %)
Duration in months Median (range) 7.5 (2.0–18.0) 7.0 (3.0–37.0) 6.0 (3.0–24.0)
Affected right shoulder 18 (50 %) 12 (35 %) 15 (42 %)
Previous frozen shoulder 6 (17 %) 4 (11 %) 4 (11 %)
Concurrent neck pain 16 (44 %) 15 (44 %) 16 (44 %)
Trauma to shoulder 2 (6 %) 11 (32 %) 3 (8 %)
Previous operation on shoulder 3 (8 %) 3 (9 %) 1 (3 %)
Dominant right side 34 (94 %) 30 (88 %) 34 (94 %)
Previous shoulder treatment 15 (42 %) 22 (65 %) 13 (36 %)
Analgesics 19 (53 %) 14 (41 %) 11 (31 %)
Participants on sick leave 17 (50 %) 16 (47 %) 15 (42 %)
Smokers 8 (22 %) 6 (18 %) 12 (33 %)
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injections claim a short time superiority in pain reduction
of about 2 weeks, compared to injections by landmarks
[48], which we consider is little as compared to the extra
resources required in terms of time and costs.
On 1 year follow-up all three groups had similar out-
come, which reflects the natural history of the condition
[14, 16, 18, 20, 49]. But the major difference in pain
relief (NPRS) and pain and function (SPADI) were re-
corded in the first 8 weeks in the intervention groups as
compared to the control group. From the patient’s per-
spective, pain relief leading to undisturbed sleep is of
great importance [50], which is not so often accredited
in studies measuring outcome over time.
One of the strengths of this study is that it is con-
ducted in line with the actual practice in treatment of
Table 3 Effect size (ES) for SPADI from baseline to 8 weeks and
12 months follow-up for the three groups
SPADI IS ISD TAU IS & ISD IS & TAU ISD & TAU
8 weeks
Mean change −40.3 −40.4 −17.4 0.2 22.8 23.0
SD 19.0 19.1 19.8 19.1 19.4 19.4
ES 0.0 1.2 1.2
12 months
Mean change −43.0 −39.8 −48.1 3.1 5.1 8.2
SD 19.6 24.7 20.4 22.3 20.0 21.4
ES 0.1 0.3 0.4
SPADI shoulder pain and disability index
IS injection steroid alone, ISD injection steroid plus saline, TAU treatment-as-usual
Table 2 SPADI, NPRS and PROM and comparison in outcomes between three groups
Injection group Steroid alone (IS) Injection group Steroid and saline (ISD) Treatment-as-usual (TAU)
Mean (SD) Mean (SD) Mean (SD)
Primary outcome variable
SPADI
At inclusion 63.8 (16.0) 60.5 (16.8) 61.9 (19.0)
4 weeks 34.1 (21.4) 30.9 (21.0) 51.9 (22.2)
8 weeks 23.8 (22.0) 20.1 (18.4) 44.4 (23.6)
12 months 16.9 (18.9) 17.2 (19.8) 11.7 (20.3)
Secondary outcome variable
NPRS
At inclusion 6.9 (1.4) 7.2 (1.6) 6.6 (2.1)
4 weeks 3.8 (2.2) 3.5 (1.7) 5.6 (2.5)
8 weeks 3.0 (2.3) 2.9 (1.6) 4.7 (2.0)
Tertiary outcome variables
Abduction (ABD)
At inclusion 53.7 (13.4) 51.0 (17.8) 50.5 (19.0)
4 weeks 62.7 (15.6) 64.7 (17.2) 53.9 (19.4)
8 weeks 68.9 (15.3) 71.9 (17.0) 56.5 (20.9)
External rotation (ER)
At inclusion 19.6 (14.7) 25.2 (17.7) 17.3 (13.5)
4 weeks 30.1 (16.3) 35.6 (15.8) 18.8 (14.8)
8 weeks 38.2 (17.6) 42.7 (17.9) 24.0 (18.1)
Internal rotation (IR)
At inclusion 38.8 (15.5) 41.1 (14.1) 40.2 (15.4)
4 weeks 49.5 (17.4) 52.7 (17.3) 43.7 (16.6)
8 weeks 57.2 (15.7) 59.6 (16.1) 47.3 (18.2)
Hand behind back (HBB)
At inclusion 0.4 (6.2) 2.2 (7.8) −0.5 (6.0)
4 weeks 5.9 (7.2) 7.5 (7.8) 1.0 (6.1)
8 weeks 10.1 (6.3) 11.2 (7.2) 4.3 (6.5)
SPADI shoulder pain and disability index, NPRS numeric pain rating scale, PROM passive range of motion
IS injection steroid alone, ISD injection steroid plus saline, TAU treatment-as-usual
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adhesive shoulder capsulitis in primary care in Norway,
i.e. intra-articular steroid injection in gleno-humeral
joint by landmarks. There are very few studies that are
close to actual practice in treatment of shoulder adhe-
sive capsulitis in primary care [25, 51]. The procedure
is safe and simple and easy to learn and cost
effective. Only 15 % of patients reported transient
side effects and the procedure was not experienced as
particularly painful. The limitations of the study are
lack of visual verification of delivery of medication in
the joint. The injected volume varied from 8 to 20 ml
and we cannot assert with certainty that the observed
Table 4 SPADI, NPRS and PROM: Differences in change scores between the two injection groups (Intervention steroid alone (IS);
Intervention steroid plus saline (ISD)) and the treatment-as-usual group (TAU)
Between groups differences in change, mean (95 % CI)
IS vs ISD IS vs TAU ISD vs TAU
Primary outcome variable
SPADI
Short-term (4 and 8 weeks)a 1.2 (−7.1 to 9.6) −20.8 (−28.9 to −12.7)*** −21.7 (−29.4 to −14.0)***
Long-term (12 months)b 0.1 (−10.4 to 10.7) −7.0 (−16.4 to 2.5) −7.0 (−16.8 to 2.8)
Secondary outcome variable
NPRS
Short-term (4 and 8 weeks)a 0.3 (0.6 to 1.2) −2.0 (−2.8 to −1.1)*** −2.2 (−3.0 to −1.4)***
Tertiary outcome variables
Abduction
Short term (4 and 8 weeks)a −4.5 (−9.7 to 0.8) 8.3 (2.3 to 14.3)** 12.7 (6.6 to 18.9)***
External rotation
Short term (4 and 8 weeks)a −0.9 (−5.8 to 4.1) 10.8 (5.8 to 15.9)*** 11.9 (6.8 to 17)***
Internal rotation
Short term (4 and 8 weeks)a −1.1 (−6.6 to 4.5) 8.8 (3.1 to 14.6)** 9.9 (4.7 to 15.1)***
Hand behind back
Short term (4 and 8 weeks)a −0.7 (−2.4 to 2.2) 5.0 (2.8 to 7.2)*** 5.1 (2.9 to 7.2)***
SPADI shoulder pain and disability index, NPRS numeric pain rating scale, PROM passive range of motion
***p < 0.001, **p < 0.01, *p < 0.05
aRepeated measures ANCOVA with baseline value as covariate. Differences and CIs from estimated marginal means
bRegression based ANCOVA with baseline value as covariate
Fig. 2 Comparison between intervention and treatment-as-usual groups from inclusion to 52 weeks for SPADI
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effect was due to distension and not to capsular rup-
ture. Longer time taken in injecting the fluid in the
joint might have introduced bias as patients might as-
sume that he or she was in the distension group,
which might have been considered the superior method
by the patients.
Conclusion
This intention to treat RCT in primary care indicates that
four injections with corticosteroid with or without disten-
sion, given with increasing intervals during 8 weeks, were
better than treatment-as-usual in adhesive capsulitis of
the shoulder. However, in the long run no difference was
found between any of the groups, indicating that natural
healing takes place independent of treatment.
Acknowledgements
Sincere thanks to Nils Ivar Aanes M.D. for being the “blinded” tester, Shruti
Sharma M.D. for data entry and calculations of SPADI and for helping in
postal follow-up. This study was supported by the General Practice Research
Fund of The Norwegian Medical Association. A grant was also received from
Dr. Trygve Gythfeldt and wife’s research fund which covered additional
expenditure for example purchase of drugs and payments to assessors.
Authors’ contributions
All authors read and approved the final manuscript. SPS, AK and AB contributed
to design of the study. SPS recruited patients, collected data and drafted the
manuscript and performed statistical analyses with help from RMN, AK and AB.
RMN helped in statistical analyses. AK and AB helped in drafting the manuscript.
SPS, AK and AB have read and approved the final manuscript.
Availability of data and materials
The clinical raw data file is available at: https://osf.io/4xvru/.
Competing interests
The authors declare that they have no competing interests.
Ethics and consent
The study is performed in accordance with the Declaration of Helsinki
and is approved by the Regional Ethical Committee (REK nord), UiT
Norges Arktiske Universitet, Postboks Langnes, 9037 Tromsø, Norway;
rek-nord@asp.uit.no. Project EUDRACT-NR 2008-004385-49; reference
200804384-7/KST017/400 and reference for change in protocol (2012) 2012/
717/REK nord. The Norwegian Social Science Data Services (reference: 19675/2/
SM) has accepted handling of data regarding personal information of patients
and given its consent for the project. The Norwegian Medicine Agency has
given its consent regarding use of Triamcinolone acetonide in this study,
reference 08/18009 (post@legemiddelverket.no). The study is registered with
ClinicalTrials.gov (https://clinicaltrials.gov/) identifier: NCT01570985 where the
protocol is also
available. Signed informed consent is obtained from all patients on
inclusion in the study.
Author details
1Research Group, Section for General Practice, Department of Global Health
and Primary Care, University of Bergen, Kalfarveien 31, N-5018 Bergen,
Norway. 2Physiotherapy Research Group, Department of Global Public Health
and Primary Care, University of Bergen, Bergen, Norway. 3Department of
Occupational Therapy, Physiotherapy and Radiography, Bergen University
College, Bergen, Norway.
Received: 24 October 2015 Accepted: 13 May 2016
References
1. Cyriax J. Textbook of Orthopaedic Medicine. Diagnosis of Soft Tissue lesions,
vol. 2. 7th ed. London: Baillie’re Tindall; 1982.
2. Lorbach O, Anagnostakos K, Scherf C, Seil R, Kohn D, Pape D. Nonoperative
management of adhesive capsulitis of the shoulder: oral cortisone
application versus intra-articular cortisone injections. J Shoulder Elbow Surg.
2010;19(2):172–9.
3. Lundberg BJ. Arthrography and Manipulation in Rigidity of the Shoulder
Joint. Acta Orthop Scand. 1965;36:35–44.
4. Shah N, Lewis M. Shoulder adhesive capsulitis: systematic review of randomised
trials using multiple corticosteroid injections. Br J Gen Pract. 2007;57(541):662–7.
5. Ombregt L, Bisschop P, Veer HJ, Van de Velde T. A System of orthopaedic
medicine. London: Saunders; 1995.
6. Kesson M, Atkins E. Orthopaedic medicine: a practical approach. Oxford:
Butterworth-Heinemann; 1998.
7. Buchbinder R, Green S. Effect of arthrographic shoulder joint distension
with saline and corticosteroid for adhesive capsulitis. Br J Sports Med.
2004;38(4):384–5.
8. Dias R, Cutts S, Massoud S. Frozen shoulder. BMJ. 2005;331:1453–6.
9. Neviaser TJ. Adhesive capsulitis. Orthop Clin North Am. 1987;18(3):439–43.
10. Hsu JE, Anakwenze OA, Warrender WJ, Abboud JA. Current review of
adhesive capsulitis. J Shoulder Elbow Surg. 2011;20(3):502–14.
11. Nagy MT, Macfarlane RJ, Khan Y, Waseem M. The frozen shoulder: myths
and realities. Open Orthop J. 2013;7:352–5.
12. Wiley AM. Arthroscopic appearance of frozen shoulder. Arthroscopy. 1991;
7(2):138–43.
13. Bunker TD, Anthony PP. The pathology of frozen shoulder. A Dupuytren-like
disease. J Bone Joint Surg (Br). 1995;77:677–83.
14. Grey RG. The natural history of “idiopathic” frozen shoulder. J Bone Joint
Surg Am. 1978;60(4):564.
15. Miller MD, Wirth MA, Rockwood Jr CA. Thawing the frozen shoulder: the
“patient” patient. Orthopedics. 1996;19(10):849–53.
16. Binder AI, Bulgen DY, Hazleman BL, Roberts S. Frozen shoulder: a long-term
prospective study. Ann Rheum Dis. 1984;43(3):361–4.
17. Hand C, Clipsham K, Rees JL, Carr AJ. Long-term outcome of frozen
shoulder. J Shoulder Elbow Surg. 2008;17(2):231–6.
18. Shaffer B, Tibone JE, Kerlan RK. Frozen shoulder. A long-term follow-up.
J Bone Joint Surg Am. 1992;74:738–46.
19. Hannafin JA, Chiaia TA. Adhesive capsulitis. A treatment approach. Clin Orthop
Relat Res. 2000;372:95–109.
20. Reeves B. The natural history of the frozen shoulder syndrome. Scand J
Rheumatol. 1975;4(4):193–6.
21. Neviaser AS, Hannafin JA. Adhesive Capsulitis. Am J Sports Med. 2010;38(11):
2346–56.
22. Griesser MJ, Harris JD, Campbell JE, Jones GL. Adhesive Capsulitis of the
Shoulder: a systematic review of the effectiveness of intra-articular
corticosteroid injections. J Bone Joint Surg Am. 2011;93:1727–33.
23. Blanchard V, Barr S, Cerisola FL. The effectiveness of corticosteroid injections
compared with physiotherapeutic interventions for adhesive capsulitis: a
systematic review. Physiotherapy. 2010;96(2):95–107.
24. Green S, Buchbinder R, Glazier R, Forbes A. Systematic review of randomised
controlled trials of interventions for painful shoulder: selection criteria,
outcome assessment, and efficacy. BMJ. 1998;316(7128):354–60.
25. van der Windt DA, Koes BW, Deville W, Boeke AJ, de Jong BA, Bouter LM.
Effectiveness of corticosteroid injections versus physiotherapy for treatment
of painful stiff shoulder in primary care: randomised trial. BMJ. 1998;
317(7168):1292–6.
26. Siegel LB, Cohen NJ, Gall EP. Adhesive capsulitis: a sticky issue. Am Fam
Physician. 1999;59(7):1843–52.
27. Buchbinder R, Green S, Forbes A, Hall S, Lawler G. Arthrographic joint
distension with saline and steroid improves function and reduces pain in
patients with painful stiff shoulder: results of a randomised, double blind,
placebo controlled trial. Ann Rheum Dis. 2004;63(3):302–9.
28. Buchbinder R, Green S, Youd JM, Johnston RV, Cumpston M. Arthrographic
distension for adhesive capsulitis (frozen shoulder). Cochrane Database Syst
Rev. 2008;1:CD007005.
29. Gam AN, Schydlowsky P, Rossel I, Remvig L, Jensen EM. Treatment of
“frozen shoulder” with distension and glucorticoid compared with
glucorticoid alone. A randomised controlled trial. Scand J Rheumatol. 1998;
27(6):425–30.
30. Corbeil V, Dussault RG, Leduc BE, Fleury J. [Adhesive capsulitis of the
shoulder: a comparative study of arthrography with intra-articular
corticotherapy and with or without capsular distension]. Can Assoc
Radiol J. 1992;43(2):127–30.
Sharma et al. BMC Musculoskeletal Disorders  (2016) 17:232 Page 9 of 10
31. Tveita EK, Tariq R, Sesseng S, Juel NG, Bautz-Holter E. Hydrodilatation,
corticosteroids and adhesive capsulitis: a randomized controlled trial.
BMC Musculoskelet Disord. 2008;9:53.
32. Uppal HS, Evans JP, Smith C. Frozen shoulder: A systematic review of
therapeutic options. World J Orthop. 2015;6(2):263–8.
33. Sharma S, Kvåle A, Bærheim A. Outcome in shoulder capsulitis (frozen
shoulder) treated with corticosteroid and corticosteroid with distension - a
randomised pilot study. Int Musculoskelet Med. 2009;3:5.
34. Williams Jr JW, Holleman Jr DR, Simel DL. Measuring shoulder function with
the Shoulder Pain and Disability Index. J Rheumatol. 1995;22(4):727–32.
35. Green S, Buchbinder R, Forbes A, Bellamy N. A standardized protocol for
measurement of range of movement of the shoulder using the Plurimeter-
V inclinometer and assessment of its intrarater and interrater reliability.
Arthritis Care Res. 1998;11:43–52.
36. Hoving JL, Buchbinder R, Green S, Forbes A, Bellamy N, Brand C, Buchanan
R, Hall S, Patrick M, Ryan P, et al. How reliably do rheumatologists measure
shoulder movement? Ann Rheum Dis. 2002;61:612–6.
37. Sharma SP, Baerheim A, Kvale A. Passive range of motion in patients with
adhesive shoulder capsulitis, an intertester reliability study over eight weeks.
BMC Musculoskelet Disord. 2015;16:37.
38. Carette S, Moffet H, Tardif J, Bessette L, Morin F, Fremont P, Bykerk V,
Thorne C, Bell M, Bensen W, et al. Intraarticular corticosteroids, supervised
physiotherapy, or a combination of the two in the treatment of adhesive
capsulitis of the shoulder: a placebo-controlled trial. Arthritis Rheum.
2003;48(3):829–38.
39. Norman GR, Streiner DL. Biostatistics The Bare Essentials. 4th ed. Shelton:
People’s Medical Publishing House-USA; 2014.
40. Lewis JA, Machin D. Intention to treat–who should use ITT? Br J Cancer.
1993;68(4):647–50.
41. Abraha I, Cherubini A, Cozzolino F, De Florio R, Luchetta ML, Rimland JM,
Folletti I, Marchesi M, Germani A, Orso M, et al. Deviation from intention to
treat analysis in randomised trials and treatment effect estimates: meta-
epidemiological study. BMJ. 2015;350:h2445.
42. Jacobs LG, Barton MA, Wallace WA, Ferrousis J, Dunn NA, Bossingham DH.
Intra-articular distension and steroids in the management of capsulitis of
the shoulder. BMJ. 1991;302(6791):1498–501.
43. Fareed DO, Gallivan Jr WR. Office management of frozen shoulder
syndrome. Treatment with hydraulic distension under local anesthesia.
Clin Orthop Relat Res. 1989;242:177–83.
44. Halverson L, Maas R. Shoulder joint capsule distension (hydroplasty): a case
series of patients with “frozen shoulders” treated in a primary care office.
J Fam Pract. 2002;51(1):61–3.
45. de Jong BA, Dahmen R, Hogeweg JA, Marti RK. Intra-articular triamcinolone
acetonide injection in patients with capsulitis of the shoulder: a
comparative study of two dose regimens. Clin Rehabil. 1998;12(3):211–5.
46. Yoon SH, Lee HY, Lee HJ, Kwack KS. Optimal Dose of Intra-articular
Corticosteroids for Adhesive Capsulitis A Randomized, Triple-Blind, Placebo-
Controlled Trial. Am J Sports Med. 2013;41(5):1133–9.
47. Piotte F, Gravel D, Moffet H, Fliszar E, Roy A, Nadeau S, Bedard D, Roy G.
Effects of repeated distension arthrographies combined with a home
exercise program among adults with idiopathic adhesive capsulitis of the
shoulder. Am J Phys Med Rehabil. 2004;83(7):537–46. quiz 547-539.
48. Lee H-J, Lim K-B, Kim D-Y, Lee K-T. Randomized Controlled Trial for Efficacy
of Intra-Articular Injection for Adhesive Capsulitis: Ultrasonography-Guided
Versus Blind Technique. Arch Phys Med Rehabil. 2009;90(12):1997–2002.
49. Vastamäki HMD, Kettunen JPTP, Vastamäki MMDP. The Natural History of
Idiopathic Frozen Shoulder: A 2- to 27-year Followup Study. Clin Orthop
Relat Res. 2012;470(4):1133–43.
50. Smith CD, Hamer P, Bunker TD. Arthroscopic capsular release for idiopathic
frozen shoulder with intra-articular injection and a controlled manipulation.
Ann R Coll Surg Engl. 2014;96(1):55–60.
51. Winters JC, Sobel JS, Groenier KH, Arendzen HJ, Meyboom-de Jong B.
Comparison of physiotherapy, manipulation, and corticosteroid injection for
treating shoulder complaints in general practice: randomised, single blind
study. BMJ. 1997;314:1320.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Sharma et al. BMC Musculoskeletal Disorders  (2016) 17:232 Page 10 of 10
